Investors bought shares of Pfizer Inc. (NYSE:PFE) on weakness during trading hours on Tuesday after an insider sold shares in the company. $191.11 million flowed into the stock on the tick-up and $70.18 million flowed out of the stock on the tick-down, for a money net flow of $120.93 million into the stock. Of all stocks tracked, Pfizer had the 5th highest net in-flow for the day. Pfizer traded down ($0.01) for the day and closed at $36.44Specifically, insider Mikael Dolsten sold 69,699 shares of the business’s stock in a transaction that occurred on Friday, March 9th. The stock was sold at an average price of $36.59, for a total transaction of $2,550,286.41. Following the completion of the sale, the insider now directly owns 120,784 shares of the company’s stock, valued at approximately $4,419,486.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Douglas M. Lankler sold 50,000 shares of the business’s stock in a transaction that occurred on Tuesday, March 13th. The stock was sold at an average price of $36.89, for a total value of $1,844,500.00. Following the sale, the insider now directly owns 133,057 shares of the company’s stock, valued at $4,908,472.73. The disclosure for this sale can be found here. Insiders sold a total of 284,557 shares of company stock valued at $10,348,114 over the last ninety days. 0.06% of the stock is currently owned by corporate insiders.
PFE has been the subject of a number of recent research reports. BMO Capital Markets set a $43.00 price objective on Pfizer and gave the stock a “buy” rating in a report on Thursday, February 15th. Barclays lowered Pfizer from an “overweight” rating to an “equal weight” rating and decreased their price objective for the stock from $41.00 to $38.00 in a report on Thursday, April 5th. Citigroup reissued a “sell” rating on shares of Pfizer in a report on Thursday, April 12th. Zacks Investment Research raised Pfizer from a “hold” rating to a “buy” rating and set a $40.00 price objective for the company in a report on Wednesday, April 11th. Finally, Jefferies Group set a $39.00 price objective on Pfizer and gave the stock a “hold” rating in a report on Monday, February 26th. Three analysts have rated the stock with a sell rating, twelve have issued a hold rating and nine have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $40.03.
Get Pfizer alerts:
The company has a debt-to-equity ratio of 0.45, a current ratio of 1.27 and a quick ratio of 0.98. The company has a market cap of $216.98 billion, a P/E ratio of 13.73, a P/E/G ratio of 1.81 and a beta of 0.91.
Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, May 1st. The biopharmaceutical company reported $0.77 EPS for the quarter, beating the consensus estimate of $0.74 by $0.03. Pfizer had a return on equity of 25.29% and a net margin of 41.29%. The business had revenue of $12.91 billion for the quarter, compared to the consensus estimate of $13.14 billion. During the same quarter in the prior year, the business earned $0.69 earnings per share. Pfizer’s revenue for the quarter was up 1.0% on a year-over-year basis. analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which was paid on Friday, June 1st. Investors of record on Friday, May 11th were paid a $0.34 dividend. The ex-dividend date of this dividend was Thursday, May 10th. This represents a $1.36 annualized dividend and a yield of 3.74%. Pfizer’s payout ratio is 51.32%.
A number of institutional investors have recently bought and sold shares of the stock. Ballew Advisors Inc bought a new stake in Pfizer during the 1st quarter valued at $102,000. Earnest Partners LLC bought a new stake in Pfizer during the 4th quarter valued at $105,000. First Dallas Securities Inc. bought a new stake in Pfizer during the 4th quarter valued at $118,000. Woodard & Co. Asset Management Group Inc. ADV bought a new stake in Pfizer during the 4th quarter valued at $118,000. Finally, Delpha Capital Management LLC bought a new stake in Pfizer during the 4th quarter valued at $126,000. Institutional investors and hedge funds own 69.47% of the company’s stock.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.